Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
NCT06538038 · View on ClinicalTrials.gov ↗
Study Summary
The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC) to better understand the safety and effectiveness of these standard of care regimens.
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG Osimertinib + Chemotherapy
Study Locations (20)
Illinois
- Advocate Good Shepherd Hospital — Barrington
- Northwestern University — Chicago
- John H Stroger Jr Hospital of Cook County — Chicago
- Advocate Illinois Masonic Medical Center — Chicago
- Northwestern Medicine Cancer Center Kishwaukee — DeKalb
- Northwestern Medicine Cancer Center Delnor — Geneva
California
- Stanford Cancer Center Emeryville — Emeryville
- Stanford Cancer Institute Palo Alto — Palo Alto
- Stanford Cancer Center South Bay — San Jose
- John Muir Health — Walnut Creek
Arkansas
- Mercy Clinic Fort Smith Communities — Fort Smith
- Mercy Research — Fort Smith
- Fowler Family Cancer Center - Jonesboro — Jonesboro
Georgia
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler: Liberty County Cancer Care — Hinesville
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler: Regional Cancer Care — Jesup
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler — Savannah
Delaware
- Bayhealth — Dover
- Satellite of Bayhealth Sussex — Milford
Alabama
- University of Alabama at Birmingham — Birmingham
District of Columbia
- Sibley Johns Hopkins University — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 538 participants |
| Start Date | 2024-09-17 |
| Est. Completion | 2029-08 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06538038
The ClinicalTrials.gov registry entry for NCT06538038 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 538 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PrECOG, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions — of which Osimertinib is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06538038 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Illinois, California, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06538038 about?
NCT06538038 is a clinical study titled "Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients". The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC) to better understand the safety ...
What is the current status of trial NCT06538038?
This trial is currently recruiting. The enrollment target is 538 participants. The study started on 2024-09-17. Estimated completion is 2029-08.
What conditions does trial NCT06538038 study?
This clinical trial studies the following conditions: Non Small Cell Lung Cancer, Stage IV Lung Cancer, Stage III Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06538038?
The interventions under investigation include: Osimertinib (DRUG), Osimertinib + Chemotherapy (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06538038?
This trial is sponsored by PrECOG, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06538038 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.